On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...

PBC patients receiving linerixibat saw statistically significant improvement in cholestatic pruritus - or relentless itch.

Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...

Individuals with primary biliary cholangitis and diabetes may experience worse outcomes, such as progression to end-stage liver disease.

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...

The FDA in 2016 granted accelerated approval to the FXR agonist as a second-line treatment for adults with PBC, either in ...

PBC is the most frequent CD-related liver disease, being regarded as the most prevalent autoimmune disorder detected in CD after Hashimoto thyroiditis, Type 1 diabetes mellitus and Sjogren syndrome.

Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...

Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...

Ipsen presents three late-breaking presentations and eight abstracts across rare cholestatic liver disease portfolio at AASLD 2024Elafibranor was granted marketing authorisation for the treatment of ...

Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected treatment-emergent adverse events Phase 2 preliminary data for chronic pruritus in ...